This article was accepted into the corpus but its outbound wikilinks were never NER-processed — typical at the deepest BFS hop or when the run's entity cap was reached. No expansion funnel to show.
| Melanoma (skin cancer) | |
|---|---|
| Name | Melanoma (skin cancer) |
| Field | Dermatology, Oncology |
Melanoma (skin cancer) is a malignant tumor of melanocytes that typically arises in skin but can originate in mucosa, eye, or meninges. It is associated with ultraviolet exposure, genetic predisposition, and immune status and requires multidisciplinary management involving dermatology, oncology, surgery, and pathology. Historical and contemporary figures, institutions, and events have shaped understanding and public awareness of melanoma.
Melanoma was described in clinical reports during the 19th century that involved physicians affiliated with institutions such as Guy's Hospital, Johns Hopkins Hospital, Royal College of Surgeons, University of Cambridge, and Massachusetts General Hospital. Landmark scientific contributions came from researchers at National Institutes of Health, Dana–Farber Cancer Institute, Memorial Sloan Kettering Cancer Center, and university departments like Harvard Medical School and Stanford University School of Medicine. Public campaigns by organizations including American Cancer Society, Cancer Research UK, World Health Organization, and Susan G. Komen influenced screening and prevention initiatives. High-profile cases involving celebrities linked awareness to figures such as Audrey Hepburn, Bob Marley, Randy Travis, Natasha Richardson, and Hugh Jackman.
Cutaneous melanoma commonly presents as a pigmented lesion exhibiting asymmetry, border irregularity, color variegation, diameter enlargement, or evolution—criteria advanced by clinicians in practices at Mayo Clinic, Cleveland Clinic, Royal Marsden Hospital, and St. Jude Children's Research Hospital. Patients may present to dermatologists who trained at programs like University College London or University of Oxford and may be referred via pathways influenced by health systems such as NHS England or Medicare (United States). Mucosal melanoma can present in sites managed by specialists from Memorial Sloan Kettering Cancer Center and MD Anderson Cancer Center, while ocular melanoma symptoms lead patients to centers like Wills Eye Hospital and Bascom Palmer Eye Institute. Symptoms prompting evaluation often involve clinicians associated with professional bodies such as the American Academy of Dermatology or European Academy of Dermatology and Venereology.
Ultraviolet radiation exposure from sunlight and tanning beds has been implicated by studies from institutions like Harvard School of Public Health, Imperial College London, Karolinska Institute, and Johns Hopkins Bloomberg School of Public Health. Genetic predisposition involves mutations and loci researched at laboratories affiliated with Broad Institute, Wellcome Trust Sanger Institute, Cold Spring Harbor Laboratory, and universities such as University of California, San Francisco and University of Pennsylvania. Notable genes and pathways studied by groups at National Cancer Institute include alterations in BRAF, NRAS, CDKN2A, and PTEN. Risk modifiers identified in cohort studies from Framingham Heart Study collaborators and registries such as Surveillance, Epidemiology, and End Results Program include phenotype and family history assessed by clinicians trained at King's College London and Edinburgh Medical School.
Diagnosis relies on histopathology and dermoscopy techniques refined in centers like Royal College of Pathologists, European Society for Medical Oncology, American Society of Clinical Oncology, and academic departments at Columbia University Irving Medical Center. Excisional biopsy with margin assessment is performed by surgeons trained at Guy's and St Thomas' NHS Foundation Trust or Barnes-Jewish Hospital, and immunohistochemical and molecular assays developed in laboratories at Stanford University School of Medicine and Yale School of Medicine detect mutations relevant to targeted therapy approvals by regulatory agencies such as Food and Drug Administration and European Medicines Agency. Imaging for metastasis employs modalities available at Johns Hopkins Hospital and UCLA Medical Center, and multidisciplinary tumor boards modeled after programs at Memorial Sloan Kettering Cancer Center guide management.
Staging follows guidelines promulgated by organizations including the American Joint Committee on Cancer and the Union for International Cancer Control, with tumor-node-metastasis schemas adopted in cancer centers like Mays Cancer Center and St. Vincent's Hospital. Pathologic classification incorporates Breslow thickness, ulceration, mitotic rate, and sentinel lymph node status as studied in trials coordinated by cooperative groups such as European Organisation for Research and Treatment of Cancer and Children's Oncology Group. Molecular subtypes defined by BRAF, NRAS, and KIT alterations inform treatment pathways developed at institutions such as MD Anderson Cancer Center and Memorial Sloan Kettering Cancer Center.
Treatment modalities include wide local excision performed by surgical teams from Cleveland Clinic and Royal Perth Hospital, sentinel lymph node biopsy techniques standardized by researchers at University of Amsterdam and Vanderbilt University Medical Center, systemic targeted therapies (vemurafenib, dabrafenib) and MEK inhibitors developed in collaboration with pharmaceutical companies and trial centers like GlaxoSmithKline and Roche. Immunotherapies such as ipilimumab, nivolumab, and pembrolizumab emerged from trials coordinated by National Cancer Institute and industry partners, with practice-changing results presented at conferences like American Society of Clinical Oncology Annual Meeting and European Cancer Congress. Radiotherapy for select sites is delivered at centers including Karolinska University Hospital and German Cancer Research Center.
Prognosis depends on stage at diagnosis; survival statistics derived from registries such as Surveillance, Epidemiology, and End Results Program, Cancer Research UK databases, and studies from Australian Institute of Health and Welfare show wide variation by country and population. Epidemiologic trends influenced by public health campaigns in nations represented at United Nations General Assembly and policies from agencies like Centers for Disease Control and Prevention indicate rising incidence in some cohorts and improved survival with early detection and novel therapies evaluated in multicenter trials including those by European Organisation for Research and Treatment of Cancer.
Prevention strategies promoted by organizations such as World Health Organization, American Cancer Society, Cancer Council Australia, and Skin Cancer Foundation emphasize UV protection, sunscreen use, and avoidance of tanning beds regulated in jurisdictions like European Union and Australia. Screening programs and public education campaigns modeled after initiatives in Scandinavia, United Kingdom, and United States leverage primary care networks associated with NHS Scotland and Kaiser Permanente and recommendations by guideline bodies such as U.S. Preventive Services Task Force.
Category:Skin cancer